ischemic stroke. Cerebral infarction
Conditions
Interventions
Intervention 1: First intervention group: Nutrition enriched with eicosapentaenoic acid with a dose of 2 grams daily. Intervention 2: Second intervention group: Nutrition enriched with eicosapentaenoi
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with ischemic stroke who are hospitalized Patients with Age over 18 years
Exclusion criteria
Exclusion criteria: Patients who are treating with Alteplase Patients with history of allergy and intolerance to cod liver oil and its derivatives Patients with platelet levels less than 50,000 Patients with bleeding peptic ulcer Pregnant women Patients with severe stroke with a NIHSS score over 20
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammatory biomarkers include high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-a), and interleukin-6 (IL-6). Timepoint: Inflammatory biomarkers including include high-sensitivity C-reactive protein, tumor necrosis factor alpha, and interleukin-6 will be measured at the beginning of the study and one month and three months after the start of the study. Method of measurement: Inflammatory biomarkers, including hs-CRP (by Latex-Enhanced Immunoturbidimetry) will be measured on a biochemical autoanalyzer (Hitachi model). Serum levels of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a) will also be measured using commercial ELISA kits with a sandwich method according to the manufacturer's instructions and optical absorption reading in an ELISA Reader at the appropriate wavelength (usually 450 nm) on fasting serum samples. All measurements will be performed in the central study laboratory in compliance with quality control protocols.;Neurologic Deficits. Timepoint: Neurologic Deficits will be measured at the beginning of the study and one month and three months after the start of the study. Method of measurement: The National Institutes of Health Stroke Scale (NIHSS) will be used to quantitatively assess neurological deficits. This 15-item scale assesses the patient's condition in various domains, including level of consciousness, motor function, vision, language, and attention. The assessment will be performed by a trained neurologist at specific study time points (baseline, one month, and three months after intervention). The total NIHSS score will be calculated and recorded for each patient.;Quality of Life. Timepoint: Quality of Life will be measured at the beginning of the study and one month and three months after the start of the study. Method of measurement: To assess the quality of life of patients, the Persian version of the Stroke-Specific Quality of Life Scale (SS-QOL) will be used. This 49-item questionnaire measure | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamaneh Masoudi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed